Lv2
134 积分 2025-03-04 加入
Acyclic cucurbit[n]uril molecular containers enhance the solubility and bioactivity of poorly soluble pharmaceuticals
21小时前
已完结
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
7天前
已完结
Double Swords in One: Novel Selective PI3K/110β PROTAC Degraders for the Treatment of Multidrug-Resistant Cancer by Activating ERS and Inhibiting P-gp
15天前
已完结
Novel Mitochondria-Targeted Asymmetric Heptamethine Cyanine Dye for Cancer Targeted NIR Imaging and Potent Necrosis and Senescence Induction with Prolonged Retention
1个月前
已完结
Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy
1个月前
已完结
Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor
2个月前
已完结
皖公网安备34019202002308
